entertainment -WSS

entertainment

author：explore 2025-10-01 00:49:05 - browse：88

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Why don't Americans have at

WSS

Report cites 'urgent' need to recruit more diverse clinical trial participants

Medicare will require more price transparency from hospitals

Doctors on social media are being harassed and cyberbullied

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

UCSF medical school apologizes for unethical prisoner experiments

The Sacklers, horror, and ‘The Fall of the House of Usher’

knowledge

entertainment

explore

Jerome Adams on the need for new antivirals for Covid

HPV cancer vaccine study demonstrates efficacy

Moonlake's readout produced a cash windfall. Risks remain

UCSF medical school apologizes for unethical prisoner experiments

Trump demands the U.S. pay no more for drugs than other countries … again

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

As demand for Covid shots wanes, Moderna seeks its next success

Doctors on social media are being harassed and cyberbullied

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

knowledge

Congress must protect the remaining independent doctors

Diversify hospital leadership teams to protect BIPOC patient health

Abortion clinic in Cancun will cater to Americans

Resistance to opioid

Ambulance rides for just $100? Advisers want major billing fixes

Removing probiotics from the NICU could threaten preemies' health

hotspot

hotspot

focus

focus